Table 2.
Description of clinical features of studies
| Study | Indication (s) | Design of Zero-profile device | Fusion level (Zero-p/CPC) | Mean follow-up time (month) | |||||
|---|---|---|---|---|---|---|---|---|---|
| C3/4 | C4/5 | C5/6 | C6/7 | C7/T1 | Zero-p | CPC | |||
| Lan et al. [7] | CR, CSM | Zero-p | 8/7 | 10/12 | 13/11 | 4/3 | 23.68 ± 1.93 | 24.39 ± 2.00 | |
| Vaishnav et al. [8] | NS | Zero-p | 2/1 | 2/3 | 8/5 | 12/13 | NS | NS | |
| Wei et al. [11] | CR, CSM | Zero-p | 5/6 | 8/21 | 15/32 | 9/9 | 15.3 ± 5.2 | 15.1 ± 5.2 | |
| He et al. [16] | CR, CSM | ROI-C | 22.6 ± 3.3 | 27.1 ± 3.5 | |||||
| Noh et al. [17] | CR | Zero-p | 8/8 | 19/24 | 11/14 | 37.6 ± 5.91 | 37.1 ± 15.7 | ||
| Lee et al. [18] | CR | Zero-p | 4/1 | 2/4 | 13/9 | 4/4 | 12.57 ± 2.09 | 28.89 ± 20.24 | |
| Son et al. [19] | CR | Zero-p | 3/2 | 4/6 | 10/14 | 4/5 | ≥ 6 | ≥ 6 | |
| Nemoto et al. [20] | CR | PREVAIL | 2/2 | 4/6 | 10/10 | 6/6 | 24 | 24 | |
| Wang et al. [21] | CSM | Zero-p | 33.59 ± 5.52 | 33.16 ± 5.97 | |||||
| Li et al. [22] | CR, CSM | Zero-p | 11/9 | 9/11 | 3/3 | 24 | 24 | ||
| Wang et al. [23] | CSM | Zero-p | 2/3 | 8/7 | 9/12 | 8/8 | 35.2 | 35.5 | |
| Yan et al. [24] | CR, CSM | Zero-p | 12/13 | 25/22 | 15.32 ± 2.13 | 14.26 ± 2.35 | |||
| Li et al. [25] | CR, CSM | Zero-p | 5/7 | 10/10 | 9/10 | 81.0 ± 4.4 | 79.0 ± 3.4 | ||
| Liu et al. [26] | CSM | Zero-p | 3/2 | 9/13 | 13/11 | 6/5 | 15.52 ± 1.93 | 16.10 ± 2.33 | |
| Shao et al. [27] | NS | Zero-p | 2/4 | 24/27 | 31/36 | 6/9 | 23.6 ± 4.5 | 25.2 ± 4.8 | |
| Yi et al. [28] | CR, CSM | Zero-p | > 12 | > 12 | |||||
| Wang et al. [29] | CR, CSM | Zero-p | 2/5 | 6/8 | 4/6 | NS | NS | ||
| Guo et al. [30] | CR, CSM | Zero-p | 13/10 | 9/13 | 9/9 | 10/12 | 9/5 | 18.5 ± 17.5 | 18.5 ± 17.5 |
| Sun et al. [31] | CR, CSM | ROI-C | 3–24 | 3–24 | |||||
| Hu et al. [32] | CR, CSM | ROI-C | 15.7 ± 2.4 | 15.7 ± 2.4 | |||||
| Sha et al. [33] | CR, CSM | ROI-C | 8/7 | 10/11 | 12/13 | 13.5 ± 1.5 | 13.5 ± 1.5 | ||
| Chang et al. [9] | CSM | Zero-p | 3/4 | 10/12 | 5/5 | 3/3 | 12–16 | 12–16 | |
| Ruan et al. [34] | CSM | ROI-C | 0/1 | 2/4 | 12/8 | 7/5 | 13.3 ± 1.9 | 14.9 ± 1.7 | |
| Zhu et al. [35] | CR, CSM | ROI-C | > 12 | > 12 | |||||
| Zhang et al. [36] | CR, CSM | ROI-C | 7/11 | 17/23 | 23/25 | 9/8 | 21.46 ± 4.51 | 21.46 ± 4.51 | |
| Gou et al. [10] | CSM | Zero-p | 2/1 | 5/4 | 7/6 | 2/5 | 6–18 | 6–18 | |
| Luo et al. [37] | CR | Zero-p | 5/3 | 9/10 | 23/22 | 13/15 | ≥ 24 | ≥ 24 | |
CR = cervical radiculopathy, CSM = cervical spondylotic myelopathy, NS = not specified